PTC-589 not checked

Edison Pharmaceuticals Inc

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.”In the company’s words, NCT02462603 on ClinicalTrials.gov
Tested for
Parkinson's Disease
Main trialPhase 2
“Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.”In the company’s words, NCT02462603 on ClinicalTrials.gov

Other drugs for Parkinson's Disease

All 87 drugs for Parkinson's Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 8 Jan 2019 Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PTC-589

Following is part of Solo: you see every change to PTC-589 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in